ReviewJACS Au2023
Chemical Basis of Combination Therapy to Combat Antibiotic Resistance.
Review in JACS Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 90 citations in OpenAlex.
- Article
- D/PVA/I-1 as an Antibiotic Adjuvant: In Vitro Synergy and Membrane Permeabilization in MDR Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Antigonococcal Activity and Cytotoxicity Screening of Three Ziziphus Species Indigenous to South Africa.Chemistry & biodiversity · 2026Article
- Dual-Functional Antibiotic Adjuvants Based on Antibacterial Polyesters With Guanidinium and Boronic Acid Motifs.Macromolecular bioscience · 2026Article
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- The Multifaceted Mechanistic Actions of Antimicrobial Nanoformulations: Overcoming Resistance and Enhancing Efficacy.Pharmaceutics · 2026Review
- Biophysical Characterization of a Carotenoprotein from Marine SpongeMarine drugs · 2026Article
- Effective combinatorial antifungal therapy using a host defense peptide mimic that self-assembles into delivery micelles.Nature biotechnology · 2026Article
- Investigation of antimicrobial synergism of actinomycin derivatives fromTurkish journal of biology = Turk biyoloji dergisi · 2026Article
- Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Exploring allosteric efflux pump inhibitors and the role of bacterial membrane potential in modulating drug resistance.Frontiers in microbiology · 2026Review
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy.Investigational new drugs · 2025Review
- Antibacterial Essential Oils as Adjuvants to Inhibit Antibiotic Resistance in Multidrug-resistant Bacteria.Chemistry & biodiversity · 2025Article
- Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.RSC advances · 2025Review
- Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC-antimicrobial resistance · 2025Review
- Structural and functional analysis of Escherichia coli membrane disruption by Ib-M peptides.PloS one · 2025Article
- Design and synthesis of natural antibacterial derivatives for ocular tuberculosis: a comprehensive review.Frontiers in pharmacology · 2025Review
- Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial resistance crisis is a global health issue requiring discovery and development of novel therapeutics. However, conventional screening of natural products or synthetic chemical libraries is uncertain. Combination therapy using approved antibiotics with inhibitors targeting innate resistance mechanisms provides an alternative strategy to develop potent therapeutics. This review discusses the chemical structures of effective β-lactamase inhibitors, outer membrane permeabilizers, and efflux pump inhibitors that act as adjuvant molecules of classical antibiotics. Rational design of the chemical structures of adjuvants will provide methods to impart or restore efficacy to classical antibiotics for inherently antibiotic-resistant bacteria. As many bacteria have multiple resistance pathways, adjuvant molecules simultaneously targeting multiple pathways are promising approaches to combat multidrug-resistant bacterial infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.